An officer of Vir Biotechnology, Inc. filed a Form 144 notice of proposed sale on November 3, 2026, covering 2,407 shares of common stock with an aggregate market value of $26,717.70.

Key Highlights

  • Filer and role: Vanina de Verneuil, identified as an officer of Vir Biotechnology, Inc.
  • Proposed sale: 2,407 shares of common stock with an aggregate market value of $26,717.70, with an approximate sale date of November 3, 2026, on NASDAQ.
  • Source of shares: 2,407 shares acquired on November 1, 2026, through restricted stock vesting from the issuer, with compensation listed as the nature of payment.
  • Prior sales: 1,343 shares of common stock were sold on November 2, 2026, for gross proceeds of $15,221.96 in the three months preceding this notice.
  • Shares outstanding: 169,215,958 shares of common stock outstanding, according to the filing.
  • Rule 10b5-1 plan: The filing indicates a plan adoption date of May 26, 2026, with Fidelity Brokerage Services LLC acting as broker and attorney-in-fact.

Vir Biotechnology Officer Proposes Common Stock Sale Following Restricted Stock Vesting

According to the Form 144 filing submitted on November 3, 2026, Vanina de Verneuil, an officer of Vir Biotechnology, Inc. (NASDAQ:VIR), provided notice of a proposed sale of 2,407 shares of the company's common stock. The filing lists an aggregate market value of $26,717.70 for the shares to be sold, with the approximate date of sale given as November 3, 2026, through Fidelity Brokerage Services LLC at 900 Salem Street, Smithfield, RI 02917.

The shares proposed for sale were acquired on November 1, 2026, through restricted stock vesting directly from the issuer. The filing identifies the nature of payment as compensation. The filing notes the adoption of a Rule 10b5-1 written trading plan on May 26, 2026. Under that plan, Daniel Tucci signed as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Vanina Huard de Verneuil.

The filing also discloses that, in the three months preceding this notice, 1,343 shares of common stock were sold on November 2, 2026, generating gross proceeds of $15,221.96. The total shares of common stock outstanding at the time of filing were reported as 169,215,958. Vir Biotechnology, Inc. is headquartered at 1800 Owens Street, Suite 900, San Francisco, California 94158.

What Was Disclosed

A Form 144 notice was filed on November 3, 2026, by an officer of Vir Biotechnology, Inc., disclosing a proposed sale of 2,407 shares of common stock valued at $26,717.70, acquired via restricted stock vesting on November 1, 2026, under a Rule 10b5-1 plan adopted May 26, 2026.